PL1962854T3 - Pochodne pirydopirazyny i ich zastosowanie jako modulatorów szlaków transdukcji sygnału - Google Patents

Pochodne pirydopirazyny i ich zastosowanie jako modulatorów szlaków transdukcji sygnału

Info

Publication number
PL1962854T3
PL1962854T3 PL06849272T PL06849272T PL1962854T3 PL 1962854 T3 PL1962854 T3 PL 1962854T3 PL 06849272 T PL06849272 T PL 06849272T PL 06849272 T PL06849272 T PL 06849272T PL 1962854 T3 PL1962854 T3 PL 1962854T3
Authority
PL
Poland
Prior art keywords
modulators
signal transduction
transduction paths
pyridopyrazine derivatives
pyridopyrazine
Prior art date
Application number
PL06849272T
Other languages
English (en)
Inventor
Irene Seipelt
Eckhard Claus
Eckhard Günther
Tilmann Schuster
Michael Czech
Emmanuel Polymeropoulos
Original Assignee
Aeterna Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeterna Zentaris Gmbh filed Critical Aeterna Zentaris Gmbh
Publication of PL1962854T3 publication Critical patent/PL1962854T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
PL06849272T 2005-11-11 2006-11-10 Pochodne pirydopirazyny i ich zastosowanie jako modulatorów szlaków transdukcji sygnału PL1962854T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73570705P 2005-11-11 2005-11-11
EP05024692A EP1790342A1 (de) 2005-11-11 2005-11-11 Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
PCT/EP2006/068323 WO2007079999A2 (de) 2005-11-11 2006-11-10 Pyridopyrazin-derivate und deren verwendung als modulatoren der signaltransduktionswege
EP06849272.7A EP1962854B1 (de) 2005-11-11 2006-11-10 Pyridopyrazin-derivate und deren verwendung als modulatoren der signaltransduktionswege

Publications (1)

Publication Number Publication Date
PL1962854T3 true PL1962854T3 (pl) 2015-10-30

Family

ID=36424666

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06849272T PL1962854T3 (pl) 2005-11-11 2006-11-10 Pochodne pirydopirazyny i ich zastosowanie jako modulatorów szlaków transdukcji sygnału

Country Status (20)

Country Link
US (1) US8937068B2 (pl)
EP (2) EP1790342A1 (pl)
JP (1) JP5448450B2 (pl)
KR (1) KR101473662B1 (pl)
CN (1) CN101330918B (pl)
AR (1) AR056216A1 (pl)
AU (1) AU2006334721B2 (pl)
BR (1) BRPI0618451A2 (pl)
CA (1) CA2628186A1 (pl)
ES (1) ES2543962T3 (pl)
IL (1) IL191160A (pl)
NO (1) NO20082509L (pl)
NZ (1) NZ595879A (pl)
PL (1) PL1962854T3 (pl)
RU (1) RU2487713C2 (pl)
SG (1) SG10201401061XA (pl)
TW (1) TWI423973B (pl)
UA (1) UA95464C2 (pl)
WO (1) WO2007079999A2 (pl)
ZA (1) ZA200803867B (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090118139A1 (en) * 2000-11-07 2009-05-07 Caliper Life Sciences, Inc. Microfluidic method and system for enzyme inhibition activity screening
AU2006313701B2 (en) * 2005-11-11 2012-05-31 Aeterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
US9458465B2 (en) * 2007-12-04 2016-10-04 Rutgers, The State University Of New Jersey Compositions and methods to modulate cell membrane resealing
US9139630B2 (en) 2006-07-11 2015-09-22 Rutgers, The State University Of New Jersey Compositions and methods for preparing recombinant MG53 and methods for optimizing same
US7893066B2 (en) * 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
EP1990342A1 (en) 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
EP2231641B1 (en) 2007-12-21 2016-06-01 UCB Biopharma SPRL Quinoxaline and quinoline derivatives as kinase inhibitors
US20100267752A1 (en) * 2008-10-15 2010-10-21 Gilead Palo Alto, Inc. 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
WO2010052448A2 (en) * 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US20130123340A1 (en) * 2010-05-11 2013-05-16 Peking University, Office Of Technology Transfer Compositions and methods for the treatment and prevention of cardiac ischemic injury
CN103430023B (zh) 2010-11-05 2016-05-04 罗格斯新泽西州立大学 血清mg53作为用于组织损伤的诊断标志物
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2508184A1 (en) * 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazine derivatives and their use
JP5792128B2 (ja) * 2011-07-29 2015-10-07 富士フイルム株式会社 １，５−ナフチリジン誘導体又はその塩
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
WO2014109414A1 (ja) 2013-01-11 2014-07-17 富士フイルム株式会社 含窒素複素環化合物またはその塩
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
MA39784B1 (fr) 2014-03-26 2021-03-31 Astex Therapeutics Ltd Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer
AU2015238305B2 (en) 2014-03-26 2020-06-18 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
JO3695B1 (ar) 2015-02-10 2020-08-27 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين)
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2016203335A1 (en) * 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
KR102703498B1 (ko) 2015-09-23 2024-09-04 얀센 파마슈티카 엔브이 신규 화합물
CN108137546B (zh) 2015-09-23 2021-07-27 詹森药业有限公司 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途
CN107619388A (zh) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
US11117894B2 (en) 2017-06-22 2021-09-14 City Of Hope Pyridopyrazine compounds and uses thereof
US12123000B2 (en) 2018-06-15 2024-10-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of PI3KC2B inhibitors for the preservation of vascular endothelial cell barrier integrity
CN111892597B (zh) * 2020-09-01 2023-07-25 山西天宏达安医药科技有限公司 一种喹喔啉基吡啶并吡嗪类化合物及其制备方法与应用
TW202320802A (zh) * 2021-07-16 2023-06-01 美商塞萊托藥品股份有限公司 Ｂｃｌ抑制劑之脂質體調配物

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3209004A (en) 1963-05-17 1965-09-28 American Home Prod 3, 6-diamino-n-(2, 2-dialkoxyethyl) pyrido[2, 3-b] pyrazine-2-carboxamides
US3180868A (en) 1963-07-24 1965-04-27 American Home Prod 3, 6-diamino-n-(substituted)pyrido[2, 3-b]-pyrazine-2-carboxamides
US3809695A (en) 1967-04-19 1974-05-07 Degussa 2,6-dichloro-3-nitro-pyridine
JPS5053394A (pl) 1973-09-20 1975-05-12
US4082845A (en) 1977-04-25 1978-04-04 Merck & Co., Inc. 3-(1-Piperazinyl)-pyrido[2,3-b]pyrazines
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
KR100369275B1 (ko) 1995-03-28 2003-05-09 스미또모 가가꾸 고오교오 가부시끼가이샤 아미노니트로피리딘류의제조방법
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
ES2154253T3 (es) 1997-12-22 2012-01-27 Bayer Healthcare Llc Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas.
WO1999043681A1 (en) 1998-02-26 1999-09-02 Neurogen Corporation 4-(4-piperidylmethylamino) substituted heteroaryl fused pyridines: gaba brain receptor ligands
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
TR200101704T2 (tr) 1998-12-15 2001-11-21 Warner-Lambert Company Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı
HRP20010473A2 (en) 1998-12-22 2002-08-31 Warner Lambert Co Combination chemotherapy
DK2223922T3 (en) 2000-04-25 2016-06-06 Icos Corp Inhibitors of HUMANPHOSPHATIDYL-inositol 3-KINASEDELTA
WO2002006213A2 (en) 2000-07-19 2002-01-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
DE60124577T2 (de) 2000-10-12 2007-09-27 Merck & Co., Inc. Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
CZ20032990A3 (cs) 2001-05-05 2004-04-14 Smithkline Beecham P. L. C. N-aroylové cyklické aminy
WO2003024448A2 (en) 2001-09-14 2003-03-27 Methylgene, Inc. Inhibitors of histone deacetylase
US7312212B2 (en) 2002-01-29 2007-12-25 Glaxo Group Limited Aminopiperidine derivatives
WO2003064431A2 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
WO2003068223A1 (en) 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
WO2003086394A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
WO2003086403A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
US20060142178A1 (en) 2002-04-08 2006-06-29 Barnett Stanley F Method of treating cancer
EP1538907A4 (en) 2002-07-02 2008-12-24 Southern Res Inst FTSZ-HEMMER AND ITS USE
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
BR0315053A (pt) 2002-10-03 2005-08-09 Targegen Inc Agentes vasculostáticos , composição, artigo e processo de preparação dos mesmos
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
US20040092521A1 (en) 2002-11-12 2004-05-13 Altenbach Robert J. Bicyclic-substituted amines as histamine-3 receptor ligands
WO2004055003A1 (en) 2002-12-13 2004-07-01 Neurogen Corporation 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
ME00541B (me) 2003-05-23 2011-10-10 Zentaris Gmbh NOVI PIRIDOPIRAZINI I NJlUHOVA UPOTREBA KAO MODULATORA KlNAZA
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
RS20050901A (sr) 2003-06-05 2007-12-31 Zentaris Gmbh., Derivati indola sa efektom na apoptozu
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
WO2005007099A2 (en) * 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
SE0302304D0 (sv) 2003-08-27 2003-08-27 Astrazeneca Ab Novel compounds
US7732442B2 (en) 2003-09-05 2010-06-08 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
JP2007520444A (ja) 2003-09-09 2007-07-26 ニューロジェン・コーポレーション 置換二環式キナゾリン−４−イルアミン誘導体
US7592340B2 (en) 2003-12-04 2009-09-22 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
WO2005072681A2 (en) 2004-01-23 2005-08-11 Amgen Inc. Vanilloid receptor ligands and their use in treatments of inflammatory and neurotic pain.
DE102004017932A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US20050256309A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
US20050256118A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
JP2008502689A (ja) 2004-06-15 2008-01-31 グラクソ　グループ　リミテッド 抗菌剤
GB0413955D0 (en) 2004-06-22 2004-07-28 Syngenta Participations Ag Chemical compounds
GB0413953D0 (en) 2004-06-22 2004-07-28 Syngenta Participations Ag Chemical compounds
EP1773831A1 (en) 2004-07-08 2007-04-18 Glaxo Group Limited Antibacterial agents
JP2008506695A (ja) 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
JP2008507543A (ja) 2004-07-22 2008-03-13 グラクソ　グループ　リミテッド 抗細菌剤
JP2008508359A (ja) 2004-08-02 2008-03-21 グラクソ グループ リミテッド 抗菌剤
JP2008509222A (ja) 2004-08-09 2008-03-27 グラクソ グループ リミテッド 抗菌剤
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
JP5209311B2 (ja) 2004-09-03 2013-06-12 メルク セローノ ソシエテ アノニム ピリジンメチレンアゾリジノン及びホスホイノシチド阻害剤としてのその使用
JP2006137723A (ja) 2004-11-15 2006-06-01 Kyowa Hakko Kogyo Co Ltd スルホンアミド誘導体
WO2006059103A2 (en) 2004-12-03 2006-06-08 Peakdale Molecular Limited Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products
JP2008528588A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
WO2006081264A1 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
EP1846416A4 (en) 2005-01-25 2009-07-01 Glaxo Group Ltd ANTIBACTERIAL AGENTS
EP1845995A4 (en) 2005-01-25 2010-03-03 Glaxo Group Ltd ANTIBACTERIAL AGENTS
AU2006216998B2 (en) 2005-02-14 2010-12-23 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
WO2006128172A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
NZ565749A (en) 2005-08-26 2010-12-24 Serono Lab Pyrazine derivatives and use as PI3K inhibitors
AU2006302179C1 (en) 2005-10-07 2013-06-20 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
AU2006313701B2 (en) 2005-11-11 2012-05-31 Aeterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases

Also Published As

Publication number Publication date
EP1962854A2 (de) 2008-09-03
IL191160A (en) 2016-03-31
AU2006334721B2 (en) 2011-08-11
EP1790342A1 (de) 2007-05-30
BRPI0618451A2 (pt) 2011-08-30
JP2009515854A (ja) 2009-04-16
AU2006334721A1 (en) 2007-07-19
TW200736253A (en) 2007-10-01
US20070123494A1 (en) 2007-05-31
TWI423973B (zh) 2014-01-21
CA2628186A1 (en) 2007-07-19
WO2007079999A2 (de) 2007-07-19
CN101330918B (zh) 2015-09-02
SG10201401061XA (en) 2014-07-30
KR101473662B1 (ko) 2014-12-17
CN101330918A (zh) 2008-12-24
RU2487713C2 (ru) 2013-07-20
JP5448450B2 (ja) 2014-03-19
UA95464C2 (en) 2011-08-10
AR056216A1 (es) 2007-09-26
NZ595879A (en) 2013-07-26
HK1125823A1 (zh) 2009-08-21
IL191160A0 (en) 2008-12-29
ES2543962T3 (es) 2015-08-26
EP1962854B1 (de) 2015-05-06
WO2007079999A3 (de) 2007-10-04
KR20080068116A (ko) 2008-07-22
RU2008123219A (ru) 2009-12-20
ZA200803867B (en) 2009-05-27
NO20082509L (no) 2008-07-23
US8937068B2 (en) 2015-01-20

Similar Documents

Publication Publication Date Title
ZA200803867B (en) Pyridopyrazine derivatives and use thereof as modulators of the signal transduction paths
ZA200710966B (en) 2-Amino-4-Phenylquinazoline derivatives and their use as HSP90 modulators
IL191139A0 (en) Novel pyridopyrazines and their use as modulators of kinases
EP1874759A4 (en) C-MET MODULATORS MODULATORS AND METHODS OF USE
IL191035A0 (en) Pharmaceutical use of substituted amides
IL191034A0 (en) Pharmaceutical use of substituted amides
EP1951680A4 (en) NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE
IL184705A0 (en) Substituted arylamine compounds and their use as 5-ht6 modulators
IL187224A0 (en) Bicyclic derivatives and pharmaceutical compositions containing the same
IL181742A0 (en) Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
IL191554A0 (en) Lactam compounds and methods of using the same
PL1736160T3 (pl) Oligosacharydy alginianowe i ich pochodne oraz ich wytwarzanie i zastosowanie
PT1802579E (pt) Derivados da 3-arilaminopiridina
IL186342A0 (en) Spirocyclic heterocycic derivaives and methods of their use
EP1951682A4 (en) NEW 2-AMINOPYRIMIDONE OR 2-AMINOPYRIDINONE DERIVATIVES AND THEIR USE
PT2380573E (pt) Acetato de eslicarbazepina e métodos de utilização
IL187026A0 (en) Substituted acrylamide derivatives and pharmaceutical compositions containing the same
DK2392335T3 (en) Use of 24-norUDCA
ZA200708371B (en) Thienopyridine derivatives and use thereof as HSP90 modulators
IL188839A0 (en) Substituted propanamide derivatives and pharmaceutical compositions containing the same
ZA200706971B (en) Substituted arylamine compounds and their use as 5-HT6 Modulators
ZA200803864B (en) Novel pyridopyrazines and their use as modulators of kinases
ZA200804872B (en) Lactam compounds and methods of using the same
EP1932527A4 (en) USE OF PHTHALIDE DERIVATIVES
AU2006332419A1 (en) The use of phthalide derivatives